Document Detail

Recurrent hope for the treatment of preterm delivery.
MedLine Citation:
PMID:  14640934     Owner:  NLM     Status:  MEDLINE    
Preterm delivery is the major determinant of infant mortality and there is a lack of treatments for this condition. Women presenting for prenatal care with a history of a spontaneous preterm delivery were assigned 17 alpha-progesterone caproate (17P) 250 mg/week i.m. between 16 and 20 weeks of gestation or placebo until 36 weeks of gestation or delivery, whichever came first. The primary outcome was preterm delivery before 37 weeks of gestation and this occurred less often in the 17P group than in the placebo group (36.3 versus 54.9%, respectively; p < 0.001). Among the infants, there was a reduction in the risk of a birth weight of < 2500 g in the 17P compared to the placebo group (27.2 versus 41%, respectively). As a result of this clinical trial, 17P should be routinely used as a preventative in women with a history of spontaneous preterm delivery.
Sheila A Doggrell
Related Documents :
18185084 - Measuring the body composition of preterm and term neonates: from research to clinical ...
18448744 - Association of preterm birth with sustained postnatal inflammatory response.
19163314 - Non-invasive distress evaluation in preterm newborn infants.
6870334 - Plasma 17-hydroxyprogesterone concentrations in ill newborn infants.
20053594 - 'i only give advice if i am asked': examining the grandmother's potential to influence ...
23488544 - Professional support and emergency visits during the first 2 weeks postpartum.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  4     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-12-03     Completed Date:  2004-03-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2363-6     Citation Subset:  IM    
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortion, Habitual / prevention & control
Anti-Bacterial Agents / therapeutic use
Clinical Trials as Topic
Hydroxyprogesterones / therapeutic use*
Obstetric Labor, Premature / prevention & control*
Pregnancy Outcome
Risk Factors
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Hydroxyprogesterones; 630-56-8/17-alpha-hydroxy-progesterone caproate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tinzaparin in the treatment of venous thromboembolism.
Next Document:  IACM 2nd Conference on Cannabinoids in Medicine.